Derrell Porter Sells Shares of ABOS
Derrell Porter sold 6,460 shares of ABOS on June 15, 2026.
Key Points
- Derrell Porter sold 6,460 shares of ABOS on June 15, 2026, at an unspecified price.
- ABOS shares traded near $2.33 with peer RA Capital Management holding over 20.9 million shares worth $49.5 million.
- Analysts including BTIG and Citigroup maintain 'Buy' ratings on ABOS with price targets ranging from $4 to $11.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 15, 2026, Derrell Porter sold 6,460 shares of ABOS. The shares were sold at an unspecified price, but ABOS shares were trading around $2.33 at the time.
What Changed in Derrell Porter's ABOS Position
Derrell Porter's recent transaction involved selling 6,460 shares of ABOS, without a set price reported for the sale. This action reflects a reduction in his holdings.
Other Institutional Activity in ABOS
RA Capital Management, L.P. increased its holdings in ABOS by 6,060,606 shares, ending with over 20.9 million shares valued at approximately $49.5 million. Sands Capital Alternatives, LLC also grew its position by 303,030 shares, now holding about 3.7 million shares worth $8.8 million. Alyeska Investment Group, L.P. significantly boosted its stake by 1,515,151 shares, bringing its total to around 2.5 million shares valued at $5.8 million. Meanwhile, Franklin Resources Inc maintained its holdings at 2.3 million shares, valued at $5.4 million.
Acumen Pharmaceuticals, Inc. Stock Down 20.2%
Shares of ABOS traded near $2.33. The stock's recent activity shows a 52-week low of $1.50 and a high of $3.50. The 50-day moving average is $2.25, while the 200-day moving average stands at $2.80.
Insider Buying and Selling at Acumen Pharmaceuticals, Inc.
Derrell Porter has been active with ABOS shares recently. On June 17, 2026, he both acquired and sold 13,040 shares at average prices of $1.07 and $2.33, respectively. On June 16, he sold 12,800 shares at $2.33, and on June 15, he sold 6,460 shares at $2.35.
Analysts Set New Price Targets
Analysts continue to show confidence in ABOS. On March 17, 2026, BTIG maintained its 'Buy' rating with an $8.00 price target. Citigroup initiated coverage with a 'Buy' rating and a $4.00 target on June 17, 2025. HC Wainwright & Co. reiterated their 'Buy' rating with a $15.00 price target back in November 2024.
About ABOS
ABOS operates within the healthcare sector, focusing on innovative treatments. The company is committed to advancing medical research and development to improve patient outcomes.
Bottom Line
Derrell Porter's recent sale of ABOS shares is a notable insider activity, although it's not uncommon for insiders to trade shares for various reasons. Institutional investors like RA Capital Management continue to show interest in ABOS, maintaining significant positions. Analysts remain optimistic, with several firms maintaining 'Buy' ratings and setting various price targets, reflecting confidence in the company's long-term potential.
Get Acumen Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ABOS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.